InMed Pharmaceuticals (INM) outlines H.R. 5371 impact on BayMedica unit

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. reported that on December 12, 2025 it issued a news release discussing the potential impact of U.S. legislation H.R. 5371, the “Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026,” on BayMedica Inc., a subsidiary of the company.

The company states that the news release includes forward-looking information and a cautionary note identifying important factors that could cause actual results to differ materially from those expectations. The news release is provided as Exhibit 99.1 and is incorporated by reference.

false 0001728328 A1 0001728328 2025-12-12 2025-12-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2025

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

InMed Pharmaceuticals Inc. Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada		V6C 3E8
(Address of Principal Executive Offices)		(Zip Code)

Company’s telephone number, including area code: (604) 669-7207

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On December 12, 2025, the Company issued a news release related to the potential impact of H.R. 5371, the “Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026” that was recently signed into law in the United States on BayMedica Inc., a subsidiary of the Company, and. A copy of the news release is attached to this Form 8-K as Exhibit 99.1 and is incorporated by reference herein. The news release contains forward-looking information and includes a cautionary note regarding such forward-looking information identifying important factors that could cause actual results to differ materially from those in the forward-looking information.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		News release, dated December 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMED PHARMACEUTICALS INC.
Date: December 12, 2025	By:	/s/ Eric A Adams
		Eric A Adams President & CEO

2

FAQ

What event did InMed Pharmaceuticals Inc. (INM) report on December 12, 2025?

InMed Pharmaceuticals Inc. reported that it issued a news release on December 12, 2025 addressing the potential impact of H.R. 5371 on its subsidiary BayMedica Inc.

How does H.R. 5371 relate to InMed Pharmaceuticals Inc. (INM)?

The company stated that H.R. 5371, the “Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026,” may have a potential impact on BayMedica Inc., its subsidiary.

What information does the InMed Pharmaceuticals Inc. (INM) news release contain?

The news release contains forward-looking information and includes a cautionary note identifying important factors that could cause actual results to differ materially from the forward-looking information.

Which subsidiary of InMed Pharmaceuticals Inc. (INM) is mentioned in connection with H.R. 5371?

The subsidiary mentioned is BayMedica Inc., which is identified as a subsidiary of InMed Pharmaceuticals Inc.

Where can investors find the full InMed Pharmaceuticals Inc. (INM) news release about H.R. 5371?

The full news release is included as Exhibit 99.1 and is incorporated by reference in the report.

What exhibits did InMed Pharmaceuticals Inc. (INM) list with this report?

The company listed Exhibit 99.1, the news release dated December 12, 2025, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.